These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 6688447)

  • 1. Endogenous ligand(s) decrease drug--protein binding in uremic sera: a fluorescence probe study.
    Robertz GM; Dengler HJ
    Klin Wochenschr; 1983 Jul; 61(13):649-53. PubMed ID: 6688447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Albumin binding in uraemia: quantitative assessment of inhibition by endogenous ligands and carbamylation of albumin.
    Dengler TJ; Robertz-Vaupel GM; Dengler HJ
    Eur J Clin Pharmacol; 1992; 43(5):491-9. PubMed ID: 1282889
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biophysical studies on the correction of uremic human serum albumin binding defects by in vitro charcoal adsorption treatment.
    Nikolaev V; Sarnatskaya V; von Appen K; Ivanov A; Rotellar E; Haspar M; Klinkmann H
    Artif Organs; 1996 Jan; 20(1):17-23. PubMed ID: 8645124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saliva and plasma levels and plasma protein binding of clofibrinic acid in uremic patients.
    Bjornsson TD; Meffin PJ; Peters FA; Blaschke TF
    Clin Pharmacol Ther; 1980 Feb; 27(2):230-5. PubMed ID: 7353345
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum levels of free non-protein bound clofibrinic acid after single dosing to patients with impaired renal function of various degrees--a multicenter study.
    Merk W; Graben N; Hartmann H; Nikolaus C; Schlierf G; Schwandt P
    Int J Clin Pharmacol Ther Toxicol; 1987 Feb; 25(2):59-62. PubMed ID: 3557732
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Binding sites of fluorescent probes on human serum albumin.
    Muller N; Lapicque F; Drelon E; Netter P
    J Pharm Pharmacol; 1994 Apr; 46(4):300-4. PubMed ID: 7519671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Underestimation of albumin content by bromocresol green, induced by drug displacers and uremia.
    Calvo R; Carlos R; Erill S
    Int J Clin Pharmacol Ther Toxicol; 1985 Feb; 23(2):76-8. PubMed ID: 3988397
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Investigation of human albumin-induced circular dichroism in dansylglycine.
    Graciani FS; Ximenes VF
    PLoS One; 2013; 8(10):e76849. PubMed ID: 24146932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction of protein binding defect in uremic sera by charcoal treatment.
    Craig WA; Evenson MA; Sarver KP; Wagnild JP
    J Lab Clin Med; 1976 Apr; 87(4):637-47. PubMed ID: 1270877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of drug binding on the esterase-like activity of human serum albumin. III. Evaluation of reactivities of the two active sites by using clofibric acid as an inhibitor.
    Kurono Y; Ohta N; Yotsuyanagi T; Ikeda K
    Chem Pharm Bull (Tokyo); 1981 Aug; 29(8):2345-50. PubMed ID: 7318041
    [No Abstract]   [Full Text] [Related]  

  • 11. A fluorescent reporter detects details of aromatic ligand interference in drug-binding sites of human serum albumin.
    Dobretsov G; Smolina N; Syrejshchikova T; Brilliantova V; Uzbekov M
    Biochem Biophys Res Commun; 2016 Sep; 478(1):462-466. PubMed ID: 27318089
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interaction mechanism between indoxyl sulfate, a typical uremic toxin bound to site II, and ligands bound to site I of human serum albumin.
    Sakai T; Yamasaki K; Sako T; Kragh-Hansen U; Suenaga A; Otagiri M
    Pharm Res; 2001 Apr; 18(4):520-4. PubMed ID: 11451040
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alteration of plasma albumin in relation to decreased drug binding in uremia.
    Boobis SW
    Clin Pharmacol Ther; 1977 Aug; 22(2):147-53. PubMed ID: 407044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A major inhibitor of phenytoin binding to serum protein in uremia.
    Mabuchi H; Nakahashi H
    Nephron; 1988; 48(4):310-4. PubMed ID: 3362278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased bilirubin-binding capacity in uremic serum caused by an accumulation of furan dicarboxylic acid.
    Tsutsumi Y; Maruyama T; Takadate A; Shimada H; Otagiri M
    Nephron; 2000 May; 85(1):60-4. PubMed ID: 10773757
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cortisol binding in uremic plasma. II. Decreased cortisol binding to albumin.
    Rosman PM; Benn R; Kay M; Wallace EZ
    Nephron; 1984; 37(4):229-31. PubMed ID: 6462312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mass spectrometric monitoring of albumin in uremia.
    Thornalley PJ; Argirova M; Ahmed N; Mann VM; Argirov O; Dawnay A
    Kidney Int; 2000 Nov; 58(5):2228-34. PubMed ID: 11044246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The binding of chloramphenicol to albumin of normal and uremic sera.
    Vodrázka Z; Jandová D; Grafnetterová J; Schück O; Kalousek I; Tomaásek R; Lachmanová J
    Biochem Pharmacol; 1978; 27(13):1717-20. PubMed ID: 708450
    [No Abstract]   [Full Text] [Related]  

  • 19. Fluorescence energy transfer study of the relationship between the lone tryptophan residue and drug binding sites in human serum albumin.
    Kasai S; Horie T; Mizuma T; Awazu S
    J Pharm Sci; 1987 May; 76(5):387-92. PubMed ID: 3656100
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduced in vitro displacement of valproic acid from protein binding by salicylate in uremic sera compared with normal sera. Role of uremic compounds.
    Dasgupta A; Jacques M
    Am J Clin Pathol; 1994 Mar; 101(3):349-53. PubMed ID: 8135194
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.